Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
Status:
Completed
Trial end date:
2018-08-18
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of brodalumab in the treatment of
moderate-to-severe psoriasis in patients who have previously failed treatment with
interleukin (IL)-17A therapies. Forty patients will be enrolled in this 16-week open-label
study. Patients will receive 210 mg of brodalumab subcutaneous injection at weeks 0, 1, and
2, followed by 210 mg every 2 weeks. The primary efficacy endpoint will be the proportion of
patients achieving a score of "0-clear" or "1-almost clear" in the sPGA score after 16 weeks
of treatment. After completion of the 16-week trial, patients may desire to continue
treatment with brodalumab.